The Cooper Companies Stock Earnings Reports

Q3 FY2025 highlights: Consolidated revenue $1.06B (up 5.7% reported, 2% organic), non-GAAP EPS $1.10 (up 15%), and free cash flow $165M. The company repurchased $52M of stock and reduced net debt to $2.35B (bank leverage 1.77x). CooperVision (CVI) revenue $718M (6.3% reported, 2.4% organic); MyDay showed double-digit growth and management says manufacturing constraints have been resolved, enabling accelerated rollout of fitting sets/trials and new private-label wins, but Clarity orders softened (notably in Asia Pac and Japan) and pure-play e‑commerce weakness in Asia pressured top-line. CooperSurgical revenues $342M (4.5% reported, 2% organic) with fertility still soft (clinics delaying capital/cycles weak in Asia Pac) but share gains in genomics/consumables and durable demand drivers long term. Financial outlook: Q4 consolidated revenue guidance $1.049B–$1.069B (2%–4% organic); Q4 non-GAAP EPS $1.10–$1.14; Q4 free cash flow ~ $100M, FY FCF ~ $385M. Management expects tariff impact to be smaller than previously estimated and plans organizational efficiency actions (restructuring/OpEx) and lower CapEx going forward. Longer term, management expects to outpace the contact-lens market in FY2026 driven by MyDay and MiSight, margin expansion from operational leverage, and ~ $2B of free cash flow generation over the next three fiscal years to support debt paydown and buybacks. Key investor risks flagged: timing of MyDay conversion from fits/trials into revenue, ongoing e‑commerce pricing pressure in Asia Pac, continued fertility softness in Asia Pac, and tariff/FX impacts.